Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kinuko Mitani

Showing results (101-110 of 148) with videos related to

Pageof 15
Sort By:
American Journal of Hematology|September 28, 2002
N-ras and p53 gene mutations in Japanese patients with myeloproliferative disordersShigeharu Tsurumi, Yuichi Nakamura, Kazuhiro Maki, et al.
International Journal of Hematology|January 12, 2010
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 studyHisashi Sakamaki, Shuichi Miyawaki, Shigeki Ohtake, et al.
International Journal of Hematology|March 17, 2023
Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12)Fumi Nakamura, Sachiko Seo, Yasuhito Nannya, et al.
International Journal of Hematology|January 5, 2021
Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapyFumi Nakamura, Honoka Arai, Yasuhito Nannya, et al.
Cancer|November 15, 2005
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 StudyShuichi Miyawaki, Hisashi Sakamaki, Shigeki Ohtake, et al.
Nature Communications|September 18, 2020
The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cellsKazuhito Naka, Ryosuke Ochiai, Eriko Matsubara, et al.
Journal of Thrombosis and Thrombolysis|May 21, 2013
Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study GroupKana Sakamoto, Hideki Nakasone, Shigeharu Tsurumi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenanceSachiko Seo, Takashi Asai, Toshiki Saito, et al.
Leukemia & Lymphoma|September 11, 2020
PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphomaFumi Nakamura, Honoka Arai, Katsuya Tokita, et al.
Leukemia Research|June 12, 2012
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation studyKiyoyuki Ogata, Keiji Kakumoto, Akira Matsuda, et al.
Pageof 15

Showing results (101-110 of 148) with videos related to

Sort By:
Pageof 15
American Journal of Hematology|September 28, 2002
N-ras and p53 gene mutations in Japanese patients with myeloproliferative disordersShigeharu Tsurumi, Yuichi Nakamura, Kazuhiro Maki, et al.
International Journal of Hematology|January 12, 2010
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 studyHisashi Sakamaki, Shuichi Miyawaki, Shigeki Ohtake, et al.
International Journal of Hematology|March 17, 2023
Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12)Fumi Nakamura, Sachiko Seo, Yasuhito Nannya, et al.
International Journal of Hematology|January 5, 2021
Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapyFumi Nakamura, Honoka Arai, Yasuhito Nannya, et al.
Cancer|November 15, 2005
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 StudyShuichi Miyawaki, Hisashi Sakamaki, Shigeki Ohtake, et al.
Nature Communications|September 18, 2020
The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cellsKazuhito Naka, Ryosuke Ochiai, Eriko Matsubara, et al.
Journal of Thrombosis and Thrombolysis|May 21, 2013
Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study GroupKana Sakamoto, Hideki Nakasone, Shigeharu Tsurumi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenanceSachiko Seo, Takashi Asai, Toshiki Saito, et al.
Leukemia & Lymphoma|September 11, 2020
PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphomaFumi Nakamura, Honoka Arai, Katsuya Tokita, et al.
Leukemia Research|June 12, 2012
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation studyKiyoyuki Ogata, Keiji Kakumoto, Akira Matsuda, et al.
Pageof 15